Neurotrophin-3 (NT-3) as a Potential Biomarker of the Peripheral Nervous System Damage Following Breast Cancer Treatment.

Tonyan, Samvel; Pospelova, Maria; Krasnikova, Varvara; Fionik, Olga; Alekseeva, Tatyana; Samochernykh, Konstantin; Ivanova, Nataliya; Vavilova, Tatyana; Vasilieva, Elena; Makhanova, Albina; Nikolaeva, Aleksandra; Bukkieva, Tatyana; Combs, Stephanie; Shevtsov, Maxim

doi:10.3390/pathophysiology30020010

journal article

Titel:: Neurotrophin-3 (NT-3) as a Potential Biomarker of the Peripheral Nervous System Damage Following Breast Cancer Treatment.
Dokumenttyp:: Journal Article
Autor(en):: Tonyan, Samvel; Pospelova, Maria; Krasnikova, Varvara; Fionik, Olga; Alekseeva, Tatyana; Samochernykh, Konstantin; Ivanova, Nataliya; Vavilova, Tatyana; Vasilieva, Elena; Makhanova, Albina; Nikolaeva, Aleksandra; Bukkieva, Tatyana; Combs, Stephanie; Shevtsov, Maxim
Abstract:: Damage to the peripheral nervous system (PNS) is a common complication of breast cancer (BC) treatment, with 60 to 80% of breast cancer survivors experiencing symptoms of PNS damage. In the current study, the levels of brain-derived neurotrophic factor (BDNF), galectin-3 (Gal-3), and neurotrophin-3 (NT-3) were measured in the blood serum of BC patients by ELISA as potential biomarkers that might indicate the PNS damage. Sixty-seven patients were enrolled in this multi-center trial and compared to the aged-matched healthy female volunteers (control group) (n = 25). Intergroup comparison of biomarker levels (i.e., Gal-3 and BDNF) did not show significant differences in any of the studied subgroups. However, intriguingly, NT-3 levels were significantly higher in BC patients as compared to healthy volunteers, constituting 14.85 [10.3; 18.0] and 5.74 [4.56; 13.7] pg/mL, respectively (p < 0.001). In conclusion, NT-3 might be employed as a potential biomarker in BC patients with clinical manifestations of PNS damage. However, further studies to validate its correlation to the degree of peripheral nervous system lesions are of high value.
Zeitschriftentitel:: Pathophysiology
Jahr:: 2023
Band / Volume:: 30
Heft / Issue:: 2
Seitenangaben Beitrag:: 110-122
Volltext / DOI:: doi:10.3390/pathophysiology30020010
PubMed:: http://view.ncbi.nlm.nih.gov/pubmed/37092524
Print-ISSN:: 0928-4680
TUM Einrichtung:: Klinik und Poliklinik für RadioOnkologie und Strahlentherapie (Prof. Combs)
BibTeX

Vorkommen:

mediaTUM Gesamtbestand Einrichtungen Schools TUM School of Medicine and Health Departments Clinical Medicine Klinik und Poliklinik für RadioOnkologie und Strahlentherapie (Prof. Combs)2023